Figure 3.

Phosphoproteomic analysis of putative pathways involved bevacizumab sensitivity and resistance. Nude mice were injected with Hec50co human endometrial cancer cells and treated with bevacizumab or vehicle (controls) for 5 weeks. Subsequently, tumors were excised and total cell lysates were isolated. Phosphorylation levels of signaling molecules from two independent experiments were assessed using Kinetworks immunoblotting approach. Results obtained from bevacizumab-treated mice were averaged, normalized to controls and presented as a fold increase/decrease in phosphorylation levels. A value of 0 on the y-axis indicates the phosphorylation levels in vehicle-treated mice.